CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC)
DOI 10.1055/s-2006-952829
Bibliografische Angaben
Nachweis in CareLit
Autor:innenW Schröder, M Campone, S Abadie, PO Witteveen, P Viens, A Du Bois
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2006
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Vascular endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs) are important mediators of tumor growth and metastasis and their expression is associated with poor prognosis in EOC. PTK/ZK is a novel, oral, angiogenesis and lymphangiogenesis inhibitor that blocks tyrosine kinase signaling from all known VEGFRs. Methods: An open label, multicenter, phase IB dose escalation study evaluating PTK/ZK with c…
Zitieren
Zitierempfehlung
W Schröder, M Campone, S Abadie, PO Witteveen, P Viens, A Du Bois (2006) A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-2006-952829
Mit CareLit weiterarbeiten